Pharma sector in good health in 2008 Dec 25, 2008
The then Finance Minister P Chidambaram halved the excise duty on pharmaceutical products from 16 per cent to eight per cent in the Budget. To read business stories in. (India Times)
Warner Chilcott and Barr Announce Settlement of Femcon(R) Fe Patent Challenge Dec 23, 2008
Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the U.S. WCRX-G. ... The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these... (PR Newswire)
Kiwis nail a Mr Big of the spam world Dec 22, 2008
These emails marketed Herbal King, Elite Herbal and Express Herbal branded pharmaceutical products, manufactured and shipped by Tulip Lab of India. The Department of Internal Affairs said in a statement released today that Atkinson had sought settlement of the New Zealand charges soon after the announced court proceedings against him in October. (The Age)
Prostrakan and Paladin Complete Agreement for Abstral(R) and Sancuso(R) Dec 22, 2008
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. (CCNMatthews Press Releases)
Anesiva Announces Changes to Its Board of Directors and Receives Notification From Nasdaq Dec 20, 2008
Anesiva, Inc. seeks to be a leader in the development of novel pharmaceutical products for pain management. The company's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. (PR Newswire)
FDA clears Covidien surgical system Dec 20, 2008
and Pharmaceutical Products division of Bermuda-based Covidien Ltd. (NYSE: COV) is based in the St. Louis area. The company is embarking on a $100 million expansion of its St. Louis County facilities over the next five years. (St. Louis Business Journal, MO)
DSM Biologics and Crucell Announce PER.C6(R) Research License Agreement with GlaxoSmithKline Dec 18, 2008
DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: ; Swiss Exchange: CRX), today announced that GlaxoSmithKline (GSK) signed a license agreement allowing GSK to research a recombinant protein on the PER.C6(R) platform ... Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies ... DSM... (PR Newswire)
Companies land Third Frontier dollars Dec 17, 2008
An expansion, the state said, would help take the company beyond the pilot stage with specialty chemicals and pharmaceutical products to full-scale manufacturing. The two-phase project, which would involve multimillion-dollar investments in building improvements and equipment, could create 40 new jobs through 2012. (Columbus Business First, OH)
QLT announces interim results of radical study evaluating Visudyne combination therapy Dec 16, 2008
Based on the six-month data review for Visudyne combination therapy and the DSMC's recommendation, the study will continue as planned (Canada Newswire)
Paladin Labs Announces Automatic Share Purchase Plan Dec 15, 2008
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. (CCNMatthews Press Releases)
Warner Chilcott to Join the Nasdaq-100 Index(R) Dec 15, 2008
The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to... (Primezone Releases)
NASDAQ Announces the Annual Re-Ranking of the NASDAQ-100 Index Dec 13, 2008
The Company is focused on marketing, selling, developing and manufacturing branded prescription pharmaceutical products in women's healthcare and dermatology in the United States. The St. David's, Bermuda, company had a market capitalization of $3. (Primezone Releases)
About 1 in 9 US kids use alternative medicine Dec 12, 2008
Medical doctors need to be careful about attacking alternative medicine, because some long-endorsed pharmaceutical products have turned out to be treatment failures, noted Dr. Kathi Kemper, a pediatrician at the Wake Forest University School of Medicine. For example, drug makers in October announced they no longer would recommend cough and cold medicines for youngsters under 4, acknowledging there is scant evidence they work in children and that they may even be dangerous in some cases. (Chippewa Falls Chippewa Herald, WI)
Morgan Lewis Adds Ballard Spahr Products Liability Leader Dec 10, 2008
The case would determine whether FDA approval of a drug serves as federal pre-emption of state law claims, having the potential to dry up a lot of the work on both the plaintiff and defense sides of pharmaceutical products liability cases. There is talk, however, of the new administration coming in and reversing via legislation any court ruling that would curb those types of state law claims. (Law.com)
Ben Venue Laboratories, Inc. Named Recipient of the Governor's Award for Outstanding Achievement in Environmental Stewardship Dec 9, 2008
Each day, employees work to fulfill the company mission to provide their customers with pharmaceutical products that improve people's health and quality of life. This commitment to others also stems deeply into how the organization gives back to the community through many avenues including responsible environmental stewardship. (PR Newswire)
Warner Chilcott Announces Receipt of Paragraph IV Certification Notices Dec 9, 2008
The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and... (PR Newswire)
Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy Dec 7, 2008
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at. (PR Newswire)
Farmers have to deal with stress, too, says Charles Dec 7, 2008
Stress now has its own line of pharmaceutical products. She added there are two signs of too much stress. (Agri-View, WI)
How green is this medicine? Dec 7, 2008
The IPC sets strict standards for drugs and other pharmaceutical products. Add to this, the wording of the amended Drugs and Cosmetics Act, which allows "only natural colouring agents as permitted under rule 26 of Prevention of Food Adulteration Rules 1955 for ayurveda, siddha and unani drugs.". (India Times, India)
EDIF revamps Ayensu Starch Factory Dec 6, 2008
Mr Bonsu said there was a global requirement for starch for the production of pharmaceutical products, beverages, floor tiles, paper and spices. Source:GNA. (Ghana Web, Ghana)
Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products Dec 6, 2008
Possible over-the-counter Pharmaceutical Products: a) Non-Prescription Drugs (With disease specific claims) b) Nutraceuticals (No disease specific claims) 2 ... Director and Chief Science Officer, Dr. Robert Melamede, stated, "There is an enormous need for these products. Recent advances in science have opened the door to develop, produce, and commercialize a variety of effective whole plant cannabinoid-based pharmaceutical products with a wide variety of important applications. Although... (PR Newswire)
QLT announces commencement of tender offer Dec 5, 2008
Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. (Canada Newswire)
Medical Futures partners with Norgine for MOVIPREP(R) in Canada Dec 5, 2008
Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL(R) for the treatment of chronic constipation and faecal impaction, MOVIPREP(R) a new generation bowel cleansing preparation, KLEAN-PREP(R) for bowel preparation prior to colonoscopy, and ORAMORPH(R) for the treatment of moderate to severe pain... (Canada Newswire)
Forest Laboratories Responds To Unsolicited Mini-Tender Offer Dec 4, 2008
These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings. SOURCE Forest Laboratories, Inc.. (PR Newswire)
ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema Dec 2, 2008
The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. (PR Newswire)
Protecting Patent Owners Nov 30, 2008
For many of us, the word "patent" evokes an image of a legal document that protects useful inventions, like machines, pharmaceutical products and manufacturing methods. Called utility patents, these patents protect the functional or technical aspects of inventions. (Forbes -- Technology)
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain Nov 29, 2008
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind. (PR Newswire)
Big Pharma Faces a Crackdown in Europe Nov 29, 2008
Europeans spend some $275 billion a year on pharmaceutical products an average of $550 for every man, woman and child. But generic medicines can cost as much as 90% less than branded drugs: total savings gained by copycat drugs entry amounted to at least $17 billion over the 2000-2007 period examined by the Commission. (Time.com)
Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg Nov 27, 2008
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. (PR Newswire)
Tainted Baby Teething Drug Kills 25 Children in... Nov 27, 2008
Pharmaceutical products that are available by prescription only in many other countries, like anti-depressants, can often be obtained over the counter. Last year, the food and drug agency ordered the disposal of counterfeit products found to contain the toxic ingredient, diethylene glycol. (Fox News)
Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company Nov 25, 2008
"The fqubed technologies have valuable applications beyond our primary focus on pharmaceutical products delivered to and through the skin," said Dan Chicoine, Nuvo's Chairman. "Collaboration agreements such as this allow us to leverage the power of our transdermal screening and high throughput formulation development platforms in complementary areas, and to improve our research capabilities so that we can more effectively develop our own topical drug pipeline." Under the collaboration, fqubed... (Canada Newswire)
Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter Nov 25, 2008
These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less... (PR Newswire)
Penwest Enters Into Second Research and Development Agreement With Otsuka Pharmaceutical Nov 25, 2008
Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural... (Primezone Releases)
Manhattan Pharmaceuticals Completes $1 Million Financing Nov 25, 2008
Other risks that may affect forward-looking information contained in this press release include, without limitation, the company's extremely limited capital resources, the possibility of being unable to obtain regulatory approval of Manhattan Pharmaceuticals, Inc.'s product candidates, the risk that the results of clinical trials may not support the company's claims, the risk that the company's product candidates may not achieve market acceptance in North America or elsewhere, the company's... (Primezone Releases)
Doctors, teachers in China may face graft charges Nov 25, 2008
Under the interpretation, medical staff face being charged with commercial bribery if they receive bribes from sales agents of pharmaceutical companies and suppliers of medical equipment, or if they help promote pharmaceutical products through their prescriptions for the benefits ... Since 2006, the SPC and SPP have reportedly cracked down on commercial bribery by focusing on areas ranging from construction, land transfer, property transactions and the purchase of medical and pharmaceutical... (Xinhuanet, China)
Escalon sells $1.1M in stock Nov 22, 2008
Founded in 1987, Escalon develops and markets ophthalmic diagnostic, surgical and pharmaceutical products along with vascular access devices. Reader Comments. (Philadelphia Business Journal, PA)
Hana Biosciences Receives NASDAQ Notification Nov 22, 2008
Additional risks that may affect such forward-looking statements include Hana's need to raise additional capital to fund its product development programs to completion, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission. (Primezone Releases)
Cheapened and cheated: Over medicalization and its damaging effects Nov 22, 2008
Since the Federal Drug Administration Modernization Act of 1997, advertising pharmaceutical products to the general public has been less restricted. Between 1996 and 2000, annual spending on direct-to-consumer advertising tripled and has been growing steadily since. (The Daily Universe, UT)
Herbal sex remedies a hazardous cocktail, experts warn Nov 21, 2008
One non-government organization, the Food and Drug Protection Foundation (LPHOM), has found several kinds of banned pharmaceutical products still being sold in markets and chemists. The foundation also found many jamu kiosks selling banned drugs to customers secretly. (Jakarta Post, Indonesia -- City)
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer Nov 20, 2008
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website. (PR Newswire)
Personalized medicine is goal of Eli Lilly Nov 20, 2008
The company engages in the development, manufacturing and sale of pharmaceutical products, including neuroscience products, such as Zyprexa for treatment of schizophrenia, and endocrinology products, such as Humalog and Humulin for treatment of diabetes. Large pharmaceutical companies such as Eli Lilly are facing significant challenges due to a lack of late-stage drugs that are nearing federal approval. (AZCentral -- Business)
Patheon Provides AcuForm(TM) Technology To Its Customers Through Ongoing Partnership with Depomed(TM) Nov 18, 2008
Website: TORONTO, Nov. 18 /CNW/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry has relaunched its alliance with Depomed(TM) (NYSE:DEPO), a specialty pharmaceutical company focused on enhancing pharmaceutical products, as part of Patheon's commitment on providing the best development and commercialization service offerings. The partnership of Patheon Inc. and Depomed(TM) unites the company's proprietary... (Canada Newswire)
Covidien Q4 sales grow 12% Nov 18, 2008
3 billion in last year s quarter, fueled by double-digit sales increases in its medical devices, pharmaceutical products and medical supplies segments ... and Pharmaceutical Products division of Bermuda-based Covidien Ltd. (NYSE: COV) is based in the St. Louis area. (St. Louis Business Journal, MO)
KV expects $3M loss in Q2 Nov 18, 2008
-based KV Pharmaceutical (NYSE: KVa, KVb) develops and markets pharmaceutical products. Reader Comments. (St. Louis Business Journal, MO)
Patheon and Senopsys Announce Alliance Nov 17, 2008
The alliance between Patheon and Senopsys is intended to deliver patient accepted pediatric formulations, line extension products and reformulated pharmaceutical products. These products will be optimized for palatability to increase patient compliance and improve health outcomes. (Canada Newswire)
Escalon(R) Reports First Quarter Fiscal 2009 Results Nov 14, 2008
" Non-GAAP Measures To supplement the Company's consolidated financial statements presented in accordance with GAAP, the Company has begun providing certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP net loss and non-GAAP loss per fully diluted share. The Company's reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These... (PR Newswire)
KV Pharmaceutical delays Q2 filing Nov 14, 2008
Brentwood-based KV Pharmaceutical (NYSE: KVa, KVb) develops and markets pharmaceutical products, including branded and generic drugs. Reader Comments. (St. Louis Business Journal, MO)
TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA Nov 13, 2008
About TheraQuest TheraQuest Biosciences, Inc. () is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. (PR Newswire)
High Temps Degrade Contact Lens Solution Nov 13, 2008
"Knowledge of the potential loss of antimicrobial activity of contact lens solutions and other pharmaceutical products when exposed to higher temperatures and the risk of such exposure when storing and transporting those products may help prevent such epidemics in the future," the researchers added. HealthDay. (MEDLINEplus)
Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy Nov 12, 2008
These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of... (PR Newswire)
KV Pharmaceutical to File Form 12b-25 on November 12, 2008 Nov 11, 2008
About KV Pharmaceutical Company KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products ... Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including... (PR Newswire)
BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update Nov 11, 2008
The Company's strategy includes revenue generation in the short-to-medium-term through the sale of natural health products and in the medium-to-long-term through development of a pipeline of pharmaceutical products. Revenue from collaboration agreement amounted to nil for the current quarter ($205,000 for the nine-month period), compared to $228,000 for the same period the previous year ($913,000 for the nine-month period). (PR Newswire)
Council awards design contract for new water plant Nov 11, 2008
The engineering firms will design the well field and plant, looking at alternatives to treating the increasing pollution found in the nation's water from pharmaceutical products. In answer to a question from Councilman Dave Ferris on the cost to build the plant, wells and distribution lines, Mach said the final number won't be known until the design has been completed. (Sioux City Journal, IO)
Lorus Therapeutics to Present At Rodman & Renshaw 10th Annual Healthcare Conference November 10-12, 2008 Nov 11, 2008
TORONTO, ONTARIO--(Marketwire - Nov. 11, 2008) - Lorus Therapeutics Inc. (TSX: - ; "Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that Dr. Aiping Young, President and CEO of Lorus, is invited to present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference being held at the New York Palace Hotel, New York. WHERE: New York Palace Hotel, Kennedy 1,... (CCNMatthews Press Releases)
Lorus Successfully Completes IND-Enabling Toxicology Studies for Lead Small Molecule Anticancer Drug LOR-253 Nov 10, 2008
TORONTO, ONTARIO--(Marketwire - Nov. 10, 2008) - Lorus Therapeutics Inc. (TSX: - ; "Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the successful completion of toxicology studies for its lead small molecule LOR-253 anticancer drug, formerly known as LT-253. LOR-253 represents a new targeted approach in cancer drug development, by inducing KLF4, a tumor... (CCNMatthews Press Releases)
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST Nov 8, 2008
About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. (PR Newswire)
ETHEX Corporation Initiated Nationwide Voluntary Recalls of Specific Lots of Five Generic Products Due to the Potential for Oversized Tablets Nov 8, 2008
Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product... (PR Newswire)
Health Care Spinoff Covidien Uses Diversity To Avoid Big Dip Nov 8, 2008
Covidien's imaging unit sells radioactive isotopes and related pharmaceutical products for disease diagnosis and treatment, as well as contrasting agents used in imaging. The firm's medical supply line includes wound-care products; operating room supplies, electrodes, needles and syringes, as well as incontinence products. (Investors Business Daily)
Takeda Wins Appeal Ruling Blocking Teva From Generic of Heartburn Medicine Nov 8, 2008
The drug was sold by TAP Pharmaceutical Products Inc., a former venture between Osaka-based Takeda and. The companies split the venture, with Takeda getting Prevacid. (Bloomberg -- Japan)
SemBioSys announces third quarter 2008 financial and operational results Nov 7, 2008
In addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco Specialty Ingredients Inc., is selling oleosome-based all natural products in the global personal care ingredient market. More information is available and can be accessed at or This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar... (Canada Newswire)
Informex to Introduce the GreenExchange at InformexUSA Nov 6, 2008
D., Rctor, DSM Pharmaceutical Products, will speak on the topic of sustainability through metabolic pathway engineered bugs ... D., Rctor, DSM Pharmaceutical Products Christopher E. Gann, Chief Executive Officer, Genomatica, Inc. In Search of Green Chemistry Excellence Since 1995, dozens of green chemical products have become commercially viable in the marketplace while a countless number of chemical production processes have been modified for greener reaction conditions. (PR Newswire)
* MEDIPHAR TAIPEI: MEDIPHAR TAIPEI professional medical exhibition and vital procurement platform Nov 6, 2008
These include: Italys largest producer/distributor of medical equipment and pharmaceutical products Artsana SPA Group (annual sales US$1. 8bn), South Korean medical instrument exporter/importer Samsung Coration (grossing US$9. (Taipei Times, Taiwan -- World)
Paladin Reports Record Third Quarter 2008 Financial Results Nov 6, 2008
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. (CCNMatthews Press Releases)
China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results Nov 5, 2008
Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit. (PR Newswire)
'Opt Out' System Could Solve Donor Organ Shortage, Says Researcher Nov 3, 2008
Dr Troyer says there is currently an illegal global trade in most body parts, with teeth, nails and bones being sold on the black market to be used as pharmaceutical products and skin being used to treat burns victims. Organs such as kidneys are also being sold by living donors for large sums of money, with organs from the third world sometimes being used for first world patients who are desperate for a life-saving operation. (Science Daily)
